Biotech firm Moderna reported a bigger-than-expected quarterly loss on Friday, hit by a charge related to its efforts to ...
In principle, mRNA vaccines are ideal for health emergencies as they can be quickly mass produced using a template. The problem is that current cell-based template production methods take too long, ...
Among the handful of drugmakers to advance a successful COVID-19 vaccine in 2020, Moderna—whose mRNA shot Spikevax was also ...
A complex molecular machine, the spliceosome, ensures that the genetic information from the genome, after being transcribed ...
Hosted on MSN8d
The spliceosome: An atomic-level look into how cells avoid errors when manufacturing mRNAA complex molecular machine, the spliceosome, ensures that the genetic information from the genome, after being transcribed ...
Moderna shares recovered from an early dip premarket despite the biotech's quarterly loss, as fading demand for its Covid-19 vaccine hurts sales. The company reported a net loss of $1.1 billion, or $2 ...
While some of the initial zeal around localized vaccine production in Africa has waned since the height of the COVID-19 ...
Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...
In a landmark achievement for both Uganda and the global medical community, the United States Patent and Trademark Office ...
TriLink BioTechnologies, a Maravai LifeSciences (MRVI) company and global provider of life science reagents and services, has signed a ...
Shares of Moderna, along with other vaccine makers, dropped further this year as lawmakers advanced President Donald Trump's ...
A complex molecular machine, the spliceosome, ensures that the genetic information from the genome, after being transcribed into mRNA precursors, is correctly assembled into mature mRNA.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results